Physicians will recognize rising death rates and increase in rare subtypes of endometrial cancer; physicians will be able to explain recent data regarding GR antagonism in ovarian cancer. This will include some new data on the ROSELLA trial of GR antagonism in ovarian cancer, and updates on our recent Uterine Cancer Program Projects.
LEARNING OBJECTIVES
At the conclusion of this activity, participants will:
• Be able to apply results of ROSELLA trial if relacorilant gets FDA approval
• Describe TCGA classifications for Endometrial cancer and their relationship with histologic categories